CFO Mark Frost Buys $25,000 in Harvard Bioscience Stock Amidst Recent Insider Accumulation
HBIO sits 78% above its 52-week low of $2.813.
Summary
Harvard Bioscience's CFO, Mark Frost, purchased $25,000 worth of common stock, adding to a recent trend of insider buying following the company's debt refinancing and reverse stock split.
Key Events · Ownership and Investor Activity · HBIO
-
CFO Open Market Purchase
Mark T. Frost, Chief Financial Officer, purchased 5,000 shares of common stock for $25,000 at $5.00 per share on March 16, 2026.
-
Continued Insider Accumulation
This purchase adds to a pattern of insider buying, with three insiders accumulating over $177,000 in shares over the past 90 days.
-
Post-Reverse Stock Split Transaction
The transaction occurred shortly after the company's 10-for-1 reverse stock split on March 13, 2026.
Analysis · HBIO · Industrial Applications And Services
This open market purchase by CFO Mark Frost signals management confidence, especially coming after the company's significant net loss in FY2025 and a recent reverse stock split. The transaction contributes to a broader pattern of insider accumulation, with three insiders collectively buying over $177,000 in the last 90 days. This insider buying could be interpreted as a positive sign that management believes the company is undervalued, particularly after addressing going concern doubts through debt refinancing.
At the time of this filing, HBIO was trading at $5.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $22.4M. The 52-week trading range was $2.81 to $9.46. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.